CDP 571

Drug Profile

CDP 571

Alternative Names: BAY 103356; BAY W 3356; CDP571; Humicade

Latest Information Update: 10 Sep 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celltech Group
  • Developer Celltech Group; PDL BioPharma
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Crohn's disease; Rheumatoid arthritis; Septic shock; Type 2 diabetes mellitus

Most Recent Events

  • 19 Aug 2003 Discontinued - Phase-II for Crohn's disease in Canada (IV)
  • 19 Aug 2003 Discontinued - Phase-II for Crohn's disease in United Kingdom (IV)
  • 19 Aug 2003 Discontinued - Phase-III for Crohn's disease in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top